Financial Data and Key Metrics Changes - ImmunoPrecise Antibodies Ltd. recorded total revenue of $5.2 million during Q2 2023, a 9.8% increase from $4.7 million in Q2 2022 [39] - Gross profit for the quarter totaled $2.8 million, a 7.9% increase compared to the same period last year, with a gross profit margin of 54%, slightly down from 55% in fiscal 2022 [40] - The company reported a net loss of $7.4 million during Q2 2023, compared to a net loss of $5 million during the same period last year, primarily due to increased investment in R&D and higher G&A costs [47] Business Line Data and Key Metrics Changes - The sales team expanded in key geographic areas, contributing to a 9.8% increase in revenue, with record quarters at both the Canadian and Utrecht sites [19] - The Canadian site reported a single monthly revenue record of over $844,000 in October [19] - BioStrand's integration into the company's offerings is expected to enhance revenue recognition and profit margins due to quicker turnaround times for in silico services [13] Market Data and Key Metrics Changes - The global organoids market is valued at over $2 billion in 2021 and is predicted to reach over $12 million by 2030, with a CAGR of 21.58% [22] - The company has seen an uptick in Wnt surrogate production and sales, indicating a growing demand for growth factors in the organoids market [22] Company Strategy and Development Direction - The company announced its voluntary delisting from the TSX Venture to create a central market for its shares on NASDAQ, enhancing long-term liquidity and shareholder value [7] - The focus is on accelerated revenue growth and sales integration of in silico capabilities, with expectations of doubling revenue from the expanded facility in Utrecht [9][55] - The strategic collaboration with BriaCell marks a shift towards non-fee-for-service based discovery programs, indicating a new business model for BioStrand [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to outperform current market conditions and achieve significant growth [11] - The integration of AI-driven platforms into drug discovery is expected to save development time and costs, enhancing the company's competitive edge [12] - The management is confident in the sustainability of the PolyTope program's efficacy against emerging SARS-CoV-2 variants, positioning the company favorably in the market [72] Other Important Information - The company has received promising feedback regarding its U.S. national patents for PolyTope, with expectations of granting being close [32] - The transition to a new accelerator facility in Utrecht has doubled lab space and increased production capacity, leading to revenue gains from new service offerings [35] Q&A Session Summary Question: Revenue trajectory and growth expectations from European resources - Management highlighted the expansion in Utrecht as ROI-generating space, anticipating significant revenue growth from high-throughput and large-scale manufacturing opportunities [52][55] Question: Timeline for AI-based product offerings and growth expectations - Management indicated that expected timelines for in silico work outputs are about four weeks, with revenue generation anticipated within eight to ten weeks after program initiation [60][64] Question: Wnt protein sales and market expectations - Management clarified that the decrease in product sales is not directly related to Wnt protein, and they expect it to capture a larger market share due to its quality and stability [66][69] Question: Commercial opportunity for PolyTope and oncology offerings - Management expressed confidence in PolyTope's sustained efficacy and its potential market position, while indicating that oncology programs are intended for out-licensing rather than clinical trials [72][82] Question: Differentiation of BioStrand technology - Management noted that the unique HYFT technology and LENSai software are key differentiators that resonate with potential partners, driving excitement in discussions [98][100]

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2023 Earnings Conference Call September 14, 2022 10:30 AM ET Company Participants Jennifer Bath - President & CEO Brad McConn - CFO Ilse Roodink - Chief Scientific Officer Barry Duplantis - VP, Client Relations Operator Good morning, and thank you for standing by. Welcome to ImmunoPrecise Antibodies First Quarter Fiscal 2022 Earnings Conference Call. Also on the call with us today are Jennifer Bath, Chief Executive Officer; Brad McConn, Chief Financial Officer; ...

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2022 Earnings Conference Call March 16, 2022 10:30 AM ET Corporate Participants John Mullaly - IR Jennifer Bath - President and Chief Executive Officer Lisa Helbling - Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to ImmunoPrecise Antibodies Fiscal Year 2022 Third Quarter Earnings Results and Business Highlights Call. Currently, all participants are in a listen-only mode. ...

The previously observed high viral clearance efficacy of TATX-03 in SARS-CoV-2-D614G-challenged hamsters implied a concerted action of the respective antibodies. Apart from anti-viral effects resulting from blocking host cell infection via synergistic effects, the demonstrated ability of TATX-03 to simultaneously bind to four different regions of the spike trimer is anticipated to promote viral clearance by the host's immune system. Recently obtained in vitro studies support this role of antibody-mediated c ...

ImmunoPrecise Antibodies - InnovationAccelerated 1 Investor Presentation December 2021 immunoprecise.com | NASDAQ:IPA, TSXV:IPA Disclosures 2 Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the "Company") securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company's securities in any jurisdiction. Neither this presentation no ...

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2022 Earnings Conference Call December 13, 2021 4:30 PM ET Company Participants Chris Chu - Johnson, Spellman & Associates, Inc., IR Dr. Jennifer Bath - President and CEO Lisa Helbling - Chief Financial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to ImmunoPrecise Antibodies Fiscal Year 2022 Second Quarter Earnings Results and Business Highlights Call. At this time, all participants ar ...

Financial Data and Key Metrics Changes - The company achieved revenues of $4.6 million during the three months ended July 31, 2021, compared to $3.8 million in 2020, representing a 22% increase in its core CRO business [23] - Gross profit was $2.5 million with a 55% gross profit margin, compared to $2.4 million and a 64% gross profit margin in 2020 [23][24] - The company recorded a net loss of $3.2 million for the quarter compared to $549,000 in Q1 2020, attributed to increased expenses and lack of grant income [28] Business Line Data and Key Metrics Changes - The company reported a 22% increase in revenue from its core CRO business, driven by an increase in both the volume and financial values of client contracts [23][12] - Significant investments were made in research and development, totaling $1.1 million compared to $309,000 in 2020, reflecting a focus on COVID-19 and other research projects [25] Market Data and Key Metrics Changes - The company is expanding its physical footprint, with the Utrecht campus anticipated to complete its move into the Accelerator building, effectively doubling the square footage of usable laboratory space [11] - The collaboration with Eurofins is expected to enhance market reach and client base, with revenue generation anticipated to begin around late Q3 2021 [38] Company Strategy and Development Direction - The company is focused on strategic growth through investments in human capital, infrastructure, and expanding its service offerings [6][8] - The collaboration with Eurofins is designed to catalyze growth in both contract research and therapeutic asset partnerships [14] - The company aims to solidify its position as a global leader in antibody discovery and contract research services [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the ongoing challenges posed by COVID-19 and emphasized the importance of their PolyTope program in addressing current and future variants [20] - The company anticipates that the fiscal year will be the most exciting yet, with ongoing strategic growth initiatives [41] Other Important Information - The company has engaged ChemPartner Biologics for clinical batch production, with first-in-human studies for SARS-CoV-2 programs expected to commence in Q1 2022 [19][35] - The company holds $40.7 million in cash as of July 31, 2021, providing sufficient reserves to sustain operations for at least the next two years [31] Q&A Session Summary Question: Update on the TATX-03 PolyTope program and timeline for preclinical results and clinical trials - Management confirmed that preclinical results are scheduled for Q4 2021, with clinical trials expected to begin in Q1 2022 [35] Question: Update on the Talem pipeline and potential partnerships - Management indicated active communication with various companies regarding Talem's pipeline assets, with several candidates moving into preclinical analysis [36][37] Question: Impact of collaboration with Eurofins on CRO business and revenue timeline - The collaboration is expected to broaden client access and generate revenue starting around late Q3 2021 [38] Question: Growth of base customers in the CRO business - Management noted continuous addition of new clients while maintaining strong relationships with existing customers, with an average contract size of around $120,000 per program [39]

Exhibit 99.2 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the three months ended July 31, 2021 and 2020 | | | Three months ended July 31, | | | --- | --- | --- | --- | | | | 2021 | 2020 | | (in thousands, except share data) | Note | $ | $ | | REVENUE | | 4,588 | 3,765 | | COST OF SALES | | 2,082 | 1,355 | | GROSS PROFIT | | 2,506 | 2,410 | | EXPENSES | | | | | Advertising | | 163 | 33 | | Amortization and depreciation | 8, 9 | 670 | 678 | | Bad debt expense (recovery ...

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q4 2021 Earnings Conference Call July 28, 2021 4:30 PM ET Company Participants John Mullaly - LifeSci Advisors Jennifer Bath - President & Chief Executive Officer Lisa Helbling - Chief Financial Officer Conference Call Participants Operator Good afternoon ladies and gentlemen and thank you for standing by. Welcome to ImmunoPrecise Antibodies Financial Results and Business Highlights Earnings Call for the Full Fiscal Year 2021. At this time, all participants are in ...